• 四川省醫(yī)學(xué)科學(xué)院·四川省人民醫(yī)院病理科（成都，610072）;

目的 　探討不同分子分型乳腺浸潤性導(dǎo)管癌手術(shù)病例標本中P53、表皮生長因子受體（EGFR）和Ki-67的表達及臨床意義。 方法 　采用免疫組織化學(xué)鏈霉菌抗生物素蛋白-過氧化物酶連接法法對2010年1月－2011年7月446例乳腺浸潤性導(dǎo)管癌患者標本進行分子分型，并同時檢測其P53、EGFR、Ki-67等的表達。 結(jié)果 　P53和Ki-67在人類表皮生長因子受體2（HER2）過表達型、基底細胞樣型、未分類型中的表達明顯強于管腔A型及管腔B型（P＜0.05）；HER2過表達型和未分類型中的EGFR表達明顯強于管腔A型及管腔B型（P＜0.05）。 結(jié)論 　在使用雌激素受體、c-erbB-2等指標對浸潤性導(dǎo)管癌進行分子分型時同時檢測P53、EGFR及Ki-67等標記物，有助于更加精準的評估腫瘤的生物學(xué)行為及預(yù)后 ，對靶向藥物的個體化治療提供參考和療效預(yù)測有重要意義。

引用本文： 王雷,宋林紅,朱鴻,付靜,李科. 不同分子分型乳腺浸潤性導(dǎo)管癌中的P53、表皮生長因子受體及Ki-67的表達及意義. 華西醫(yī)學(xué), 2012, 27(9): 1349-1353. doi: 復(fù)制

版權(quán)信息： ?四川大學(xué)華西醫(yī)院華西期刊社《華西醫(yī)學(xué)》版權(quán)所有，未經(jīng)授權(quán)不得轉(zhuǎn)載、改編

1. 　Elston CW, Ellis IO. Classification of malignant breast disease[M]// Elston CW, Ellis IO. The breast. Systemic pathology. 3rd ed. Edinburgh: Churchill Livingstone, 1998: 239-247.
2. 　唐平, 魏兵, Hicks DG, 等. 乳腺癌的分子分類及其臨床應(yīng)用[J]. 中華病理學(xué)雜志, 2009, 38(1): 13-17.
3. 　Setiawan VW, Monroe KR, Wilkens LR, et al. Breast cancer risk factors defined by estrogen and progesterone receptor status: the multiethnic cohort study[J]. Am J Epidemiol, 2009, 169(10): 1251-1259.
4. 　Demonty G, Bernard-Marty C, Puglisi F, et al. Progress and new standards of care in the management of HER-2 positive breast cancer[J]. Eur J Cancer, 2007, 43(3): 497-509.
5. 　林敏, 陳忠清, 包蕓, 等. 乳腺浸潤性導(dǎo)管癌分子亞型與臨床病理特征及預(yù)后的關(guān)系[J]. 中華病理雜志, 2010, 39(6): 372-376.
6. 　袁中玉, 王樹森, 朱美琴, 等. 不同分子亞型乳腺癌的臨床特征和預(yù)后[J]. 中華腫瘤雜志, 2008, 30(6): 456-461.
7. 　Calza S, Hall P, Auer G, et al. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients[J]. Breast Cancer Res, 2006, 8(4): R34.
8. 　Shirley SH, Rundhaug JE, Tian J, et al. Transcriptional regulation of estrogen receptor-alpha by P53 in human breast cancer cells[J]. Cancer Res, 2009, 69(16): 3405-3414.
9. 　Mao XY, Fan CF, Zheng HC, et al. P53 nuclear accumulation and ER alpha expression in ductal hyperplasia of breast in a cohort of 215 Chinese women [J]. J Exp Clin Cancer Res, 2010, 29(8): 112.
10. 　曾敏. survivin 在乳腺癌中的表達及其與P53基因的關(guān)系[J]. 中華實用診斷與治療雜志, 2009, 23(12): 1181-1183.
11. 　Yuen PM, Ng PS, Leung PL, et al. Outcome in laparoscopic management of persistent adnexal mass during the second trimester of the second trimester of pregnancy[J]. Surg Endosc, 2004, 18(9): 1354-1357.
12. 　Hanprasertpong J, Tungsinmunkong K, Chichareon S, et al. Correlation of P53 and Ki-67 (MIB-1) expressions with clinicopathological feat ures and prognos is of early stage cervical squamous cell carcinomas[J]. J Obstet Gynaecol Res, 2010, 36(3): 572-580.
13. 　Tzaida O, Gogas H, Dafni U, et al. Evaluation of the prognostic and predictive value of HER-1/EGFR in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy[J]. Oncology, 2007, 72(5-6): 388-396.
14. 　Wu M, Jung L, Zhou J, et al. Dissecting genetic requirements of human breast tumorigenes is in a tissue transgenic model of human breast cancer in mice[J]. Proc Natl Acad Sci USA, 2009, 106(17): 7022-7077.
15. 　Zhang Y, Opresko L, Shankaran H, et al. HER/ErbB receptorin teractions and signaling patterns in human mammary epithelialcells[J]. BMC Cell Biol, 2009, 10: 78-80.
  1. 1. 　Elston CW, Ellis IO. Classification of malignant breast disease[M]// Elston CW, Ellis IO. The breast. Systemic pathology. 3rd ed. Edinburgh: Churchill Livingstone, 1998: 239-247.
  2. 2. 　唐平, 魏兵, Hicks DG, 等. 乳腺癌的分子分類及其臨床應(yīng)用[J]. 中華病理學(xué)雜志, 2009, 38(1): 13-17.
  3. 3. 　Setiawan VW, Monroe KR, Wilkens LR, et al. Breast cancer risk factors defined by estrogen and progesterone receptor status: the multiethnic cohort study[J]. Am J Epidemiol, 2009, 169(10): 1251-1259.
  4. 4. 　Demonty G, Bernard-Marty C, Puglisi F, et al. Progress and new standards of care in the management of HER-2 positive breast cancer[J]. Eur J Cancer, 2007, 43(3): 497-509.
  5. 5. 　林敏, 陳忠清, 包蕓, 等. 乳腺浸潤性導(dǎo)管癌分子亞型與臨床病理特征及預(yù)后的關(guān)系[J]. 中華病理雜志, 2010, 39(6): 372-376.
  6. 6. 　袁中玉, 王樹森, 朱美琴, 等. 不同分子亞型乳腺癌的臨床特征和預(yù)后[J]. 中華腫瘤雜志, 2008, 30(6): 456-461.
  7. 7. 　Calza S, Hall P, Auer G, et al. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients[J]. Breast Cancer Res, 2006, 8(4): R34.
  8. 8. 　Shirley SH, Rundhaug JE, Tian J, et al. Transcriptional regulation of estrogen receptor-alpha by P53 in human breast cancer cells[J]. Cancer Res, 2009, 69(16): 3405-3414.
  9. 9. 　Mao XY, Fan CF, Zheng HC, et al. P53 nuclear accumulation and ER alpha expression in ductal hyperplasia of breast in a cohort of 215 Chinese women [J]. J Exp Clin Cancer Res, 2010, 29(8): 112.
  10. 10. 　曾敏. survivin 在乳腺癌中的表達及其與P53基因的關(guān)系[J]. 中華實用診斷與治療雜志, 2009, 23(12): 1181-1183.
  11. 11. 　Yuen PM, Ng PS, Leung PL, et al. Outcome in laparoscopic management of persistent adnexal mass during the second trimester of the second trimester of pregnancy[J]. Surg Endosc, 2004, 18(9): 1354-1357.
  12. 12. 　Hanprasertpong J, Tungsinmunkong K, Chichareon S, et al. Correlation of P53 and Ki-67 (MIB-1) expressions with clinicopathological feat ures and prognos is of early stage cervical squamous cell carcinomas[J]. J Obstet Gynaecol Res, 2010, 36(3): 572-580.
  13. 13. 　Tzaida O, Gogas H, Dafni U, et al. Evaluation of the prognostic and predictive value of HER-1/EGFR in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy[J]. Oncology, 2007, 72(5-6): 388-396.
  14. 14. 　Wu M, Jung L, Zhou J, et al. Dissecting genetic requirements of human breast tumorigenes is in a tissue transgenic model of human breast cancer in mice[J]. Proc Natl Acad Sci USA, 2009, 106(17): 7022-7077.
  15. 15. 　Zhang Y, Opresko L, Shankaran H, et al. HER/ErbB receptorin teractions and signaling patterns in human mammary epithelialcells[J]. BMC Cell Biol, 2009, 10: 78-80.